Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen. Funded by the National Cancer Institute through the company's first NCI grant awarded December last year, its lead candidate drug Vicrostatin was combined with a drug-eluting gel and applied into the peritoneum for sustained release of the drug directly to ovarian cancer metastatic tumors.
"The results our scientists achieved are exceptional", said Thomas C. Chen, MD, Ph.D., the company's Chief Medical Officer, "and suggest an equivalent human treatment for ovarian cancer patients is feasible. The implications for this treatment are equally compelling as 75% of women first diagnosed with ovarian cancer have stage III or stage IV metastatic disease and 80% of those women fail to survive longer than 20 months post diagnosis. This approach is early but if we are able to achieve comparable results in human clinical trials with women suffering from ovarian cancer this treatment could considerably change the current standard of care."